

William Shaw, Ph.D., Director

11813 West 77th Street, Lenexa, KS 66214

(913) 341-8949

Fax (913) 341-6207

Requisition #: Patient Name: 293081

Jonathan Barnett

Physician:

Date of Collection:

2/25/2013

Patient Age:

56

Time of Collection:

04:00 AM

Patient Sex:

М

Print Date:

03/02/2013



Organic Acids Test - Nutritional and Metabolic Profile

Metabolic Markers in Urine

Reference Range (mmol/mol creatinine) **Patient**

Reference Population - Males Age 13 and Over

Citramalic 0.11 - 2.0 0.98 5-Hydroxymethyl-2-furoic 5 18 H 27 3 3-Oxoglutaric 5 0.11 0.09 6 Furan-2,5-dicarboxylic 5 13 H 16 6 Furan-2,5-dicarboxylic 5 13 H 16 6 Furancarbonylglycine 5 2.3 0.22 22 42 42 4 Arabinose 5 Carboxycitric 5 20 T.1 7 Tricarballylic 5 0.58 0.25 6 Arabinose 1 2-Hydroxyphenylacetic 1 2-Hydroxyphenylacetic 5 18 15 6 4-Hydroxyphenylacetic 5 18 15 6 4-Hydroxyphenylacetic 5 241 234 6 3-Indoleacetic 5 5.3 3.1 6 4-Cresol (C. difficile) 5 39 7.5	and Fungal Markers											
3 3-Oxoglutaric	Citramalic	0.11	-	2.0		0.98			6 .9	18		
Furan-2,5-dicarboxylic ≤ 13 H 16 Furancarbonylglycine ≤ 2.3 0.22 0.22 Tartaric ≤ 5.3 0.30 0.30 Arabinose ≤ 20 H 135 Carboxycitric ≤ 20 7.1 1 Tricarballylic ≤ 0.58 0.25 0.25 Ilabsorption and Bacterial Markers 2-Hydroxyphenylacetic 0.03 - 0.47 0.27 0.27 4-Hydroxyphenylacetic ≤ 18 15 0.47 0.44 0.44 4-Hydroxybippuric ≤ 14 13 0.47 0.44	5-Hydroxymethyl-2-furoi		≤	18	н	27		- <	27			
Furancarbonylglycine ≤ 2.3 0.22 0.25 Tartaric ≤ 5.3 0.30 0.30 Arabinose ≤ 20 H 135 Carboxycitric ≤ 20 7.1 7.1 Tricarballylic ≤ 0.58 0.25 0.25 Jabsorption and Bacterial Markers 2-Hydroxyphenylacetic ≤ 18 15 4-Hydroxyphenylacetic ≤ 18 15 0.47 4-Hydroxyphenylacetic ≤ 14 13 0.47 4-Hydroxyhippuric ≤ 14 13 0.47 4-Hydroxyhippuric ≤ 14 13 0.47 4-Hippuric ≤ 241 234 234 3-Indoleacetic ≤ 6.8 1.7 1.7 Succinic ≤ 5.3 3.1 3.1 HPHPA (Clostridia Marker) ≤ 102 H 112 112	3-Oxoglutaric		≤	0.11		0.09						 0.09
Tartaric ≤ 5.3 0.30 0.30 Arabinose ≤ 20 H 135 Carboxycitric ≤ 20 7.1 Tricarballylic ≤ 0.58 0.25 absorption and Bacterial Markers 2.Hydroxyphenylacetic 0.03 - 0.47 0.27 4-Hydroxyphenylacetic ≤ 18 15 4-Hydroxybenzoic 0.01 - 0.73 0.47 4-Hydroxyhippuric ≤ 14 13 Hippuric ≤ 241 234 3-Indoleacetic ≤ 6.8 1.7 Succinic ≤ 5.3 3.1 HPHPA (Clostridia Marker) ≤ 102 H 112	Furan-2,5-dicarboxylic		≤	13	н	16		16				
Arabinose ≤ 20 H 135 Carboxycitric ≤ 20 7.1 7.1 Tricarballylic ≤ 0.58 0.25 0.25 absorption and Bacterial Markers 2-Hydroxyphenylacetic 0.03 - 0.47 0.27 0.27 4-Hydroxyphenylacetic ≤ 18 15 15 4-Hydroxybenzoic 0.01 - 0.73 0.47 0.47 4-Hydroxyhippuric ≤ 14 13 Hippuric ≤ 241 234 3-Indoleacetic ≤ 6.8 1.7 Succinic ≤ 5.3 3.1 HPHPA (Clostridia Marker) ≤ 102 H 112	Furancarbonylglycine		≤	2.3		0.22	0.22					
Carboxycitric ≤ 20 7.1 7.1 Tricarballylic ≤ 0.58 0.25 absorption and Bacterial Markers 2-Hydroxyphenylacetic 0.03 - 0.47 0.27 4-Hydroxyphenylacetic ≤ 18 15 4-Hydroxybenzoic 0.01 - 0.73 0.47 4-Hydroxyhippuric ≤ 14 13 4-Hydroxyhippuric ≤ 241 234 3-Indoleacetic ≤ 6.8 1.7 Succinic ≤ 5.3 3.1 HPHPA (Clostridia Marker) ≤ 102 H	Tartaric		S	5.3		0.30	0.30>	and Land				
Tricarballylic ≤ 0.58 0.25 absorption and Bacterial Markers 2-Hydroxyphenylacetic 0.03 - 0.47 0.27 4-Hydroxyphenylacetic ≤ 18 15 4-Hydroxybenzoic 0.01 - 0.73 0.47 4-Hydroxyhippuric ≤ 14 13 Hippuric ≤ 241 234 3-Indoleacetic ≤ 6.8 1.7 Succinic ≤ 5.3 3.1 HPHPA (Clostridia Marker) ≤ 102 H 112	Arabinose		≤	20	н	135						
absorption and Bacterial Markers 2-Hydroxyphenylacetic 4-Hydroxyphenylacetic 5 18 15 4-Hydroxybenzoic 4-Hydroxyhippuric 5 14 13 6 241 3-Indoleacetic 5 5.3 3.1 HPHPA (Clostridia Marker) 5 0.03 - 0.47 0.27 0.27 0.27 0.27 0.27 0.47	Carboxycitric		≤	20		7.1			7.1 >			
2-Hydroxyphenylacetic 4-Hydroxyphenylacetic ≤ 18 15 4-Hydroxybenzoic 0.01 - 0.73 0.47 4-Hydroxyhippuric ≤ 14 13 Hippuric ≤ 241 234 3-Indoleacetic ≤ 6.8 1.7 Succinic HPHPA (Clostridia Marker) ≤ 102 H 112	Tricarballylic		≤	0.58		0.25		T	Q.25		AND TO	
4-Hydroxyphenylacetic ≤ 18 15 4-Hydroxybenzoic 0.01 - 0.73 0.47 4-Hydroxyhippuric ≤ 14 13 Hippuric ≤ 241 234 3-Indoleacetic ≤ 6.8 1.7 Succinic ≤ 5.3 3.1 HPHPA (Clostridia Marker) ≤ 102 H 112	sorption and Bacterial Ma	ers										
4-Hydroxybenzoic 0.01 - 0.73 0.47 4-Hydroxyhippuric ≤ 14 13 Hippuric ≤ 241 234 3-Indoleacetic ≤ 6.8 1.7 Succinic ≤ 5.3 3.1 HPHPA (Clostridia Marker) ≤ 102 H 112	2-Hydroxyphenylacetic	0.03	-	0.47		0.27				0.27	- 10 m	
4-Hydroxyhippuric ≤ 14 13 Hippuric ≤ 241 234 3-Indoleacetic ≤ 6.8 1.7 Succinic ≤ 5.3 3.1 HPHPA (Clostridia Marker) ≤ 102 H 112			≤	18		15						15
Hippuric ≤ 241 234 3-Indoleacetic ≤ 6.8 1.7 Succinic ≤ 5.3 3.1 HPHPA (Clostridia Marker) ≤ 102 H 112 112	4-Hydroxyphenylacetic										rition many	
3-Indoleacetic ≤ 6.8 1.7 1.7 Succinic ≤ 5.3 3.1 HPHPA (Clostridia Marker) ≤ 102 H 112 112		0.01	-	0.73							(4)	
Succinic ≤ 5.3 3.1 HPHPA (Clostridia Marker) ≤ 102 H 112 112	4-Hydroxybenzoic	0.01				0.47				1 4	(47)	13
HPHPA (Clostridia Marker) ≤ 102 H 112	4-Hydroxybenzoic 4-Hydroxyhippuric	0.01	≤	14		0.47				I •	<u>(.47)</u>	
	4-Hydroxybenzoic 4-Hydroxyhippuric Hippuric	0.01	YI YI	14 241		0.47 13 234		1.7			2.47	13
4-Cresol (C. difficile) ≤ 39 7.5	4-Hydroxybenzoic 4-Hydroxyhippuric Hippuric 3-Indoleacetic	0.01	N	14 241 6.8		0.47 13 234 1.7		1.7>				13
	4-Hydroxybenzoic 4-Hydroxyhippuric Hippuric 3-Indoleacetic Succinic	0.01	N N N	14 241 6.8 5.3	н	0.47 13 234 1.7 3.1						13

Testing performed by The Great Plains Laboratory, Inc., Lenexa, Kansas. The Great Plains Laboratory has developed and determined the performance characteristics of this test. This test has not been evaluated by the U.S. FDA; the FDA does not currently regulate such testing.

equi	sition #: 293081						Physician:
atier	nt Name: Jonathan Barnet	t					Date of Collection: 2/25/2013
leta	bolic Markers in Urine	Reference Ra	-71.71	500	P	atient	Reference Population - Males Age 13 and Over
Ох	ralate Metabolites			W STANK	elver s	PROPERTY OF THE STATE OF THE ST	
20	Glyceric	0.21		4.9		1.1	1.1
21	Glycolic	18	.5%	81		41	41
22	Oxalic	8.9	**	67		66	
GI	ycolytic Cycle Metabolites						
23	Lactic	0.74	-	19		10	10
24	Pyruvic	0.28		6.7		5.8	5.8
25	2-Hydroxybutyric		≤	1.2		0.74	0.74
Kr	ebs Cycle Metabolites		WW.			Mi si	
26	Succinic		≤	5.3		3.1	3.1
27	Fumaric		≤	0.49		0.40	-0.40
28	Malic		≤	1.1		0.32	432
29	2-Oxoglutaric		≤	18	н	19	19
30	Aconitic	4.1		23		14	14
31	Citric	2.2	•	260	Н	354	354
Ne	eurotransmitter Metabolites						
32	Homovanillic (HVA) (dopamine)	0.39	-	2.2		1.6	1.6
33	Vanillylmandelic (VMA) (norepinephrine, epinephri	0.53		2.2		1.5	1.5
34	HVA / VMA Ratio	0.32	-	1.4		1.1	(1)
35	5-Hydroxyindoleacetic (5-HIAA (serotonin))	≤	2.9		0.91	09
36	Quinolinic	0.52	-	2.4		2.2	22
37	Kynurenic	0.12	•	1.8		1.6	1.6
38	Quinolinic / 5-HIAA Ratio		≤	2.5		2.4	2.4
Py	rimidine Metabolites - Fola	te Metabolis	sm				
39	Uracil		≤	6.9		3.0	3.0
10	Thymine		5	0.36		0.21	(0,2)

Requisition #: 293	31					Physician:				
Patient Name: Jona	an Barnett					Date of Collection: 2/25/2013				
letabolic Markers in Urir		Reference Range mol/mol creatinine)		Patient		Reference Population - Males Age 13 and Over				
Ketone and Fatty Aci	Oxidation			5.4			Simil			
41 3-Hydroxybutyric		≤	1.9		0.94	0.94				
42 Acetoacetic		S	10		0.65	0.65				
43 4-Hydroxybutyric		≤	4.3		1.7	<u> </u>				
44 Ethylmalonic	0.13	-	2.7		1.5	(1.5)				
45 Methylsuccinic		<	2.3		2.1		- (2.1			
5000 Sept. 1000 Sept.							۷.1			
46 Adipic			2.9		1.7	1.7				
47 Suberic		≤	1.9	Н	2.1	2.1				
48 Sebacic		≤	0.14	Н	0.18	0.18				
Vitamin B12 49 Methylmalonic *		≤	2.3		1.9		.9>—			
Vitamin B6										
50 Pyridoxic (B6)		≤	26		5.7	5.7				
Vitamin B5		187700	1000		714/47					
51 Pantothenic (B5)		≤	5.4	н	11	<u></u>				
Vitamin B2 (Riboflavin)		120								
52 Glutaric #		S	0.43		0.27	Q.2	465			
Vitamin C	40		200		47					
53 Ascorbic	10	•	200	L	4.7	4.7				
Vitamin Q10 (CoQ10)	1000	100	0.0		7.0					
54 3-Hydroxy-3-methylg		5	26		7.8	7.8				
Glutathione Precursor and (50°									
55 N-Acetylcysteine (NA)	S	0.13		0.07	(0)				
Biotin (Vitamin H)										
56 Methylcitric *	0.15	-	1.7	н	2.1	2.1				

^{*} A high value for this marker may indicate a deficiency of this vitamin.

	sition #: 293081	kamatt			Physician:	2/	25/2013		
		Reference Ran	the state of the s	Patient	Date of Collection: 2/25/2013 Reference Population - Males Age 13 and Over				
lne	dicators of Detoxification	on							
7	Pyroglutamic	5.7 -	25	20				20	
8	Orotic	≤	0.46	0.32			1	Q.32	
9	2-Hydroxyhippuric	≤	0.86	0.45			Q.45>		
Ar	nino Acid Metabolites								
0	2-Hydroxyisovaleric	≤	0.41	0	0.00		1	Constitutions	986
1	2-Oxoisovaleric	≤	1.5	0.31	0.31	<u> </u>	I		
2	3-Methyl-2-oxovaleric	S	0.56	0.46		MENAGOS.		—0.46	>
3	2-Hydroxyisocaproic	S	0.39	0.01	0.01	Same To			
4	2-Oxolsocaproic	\$	0.34	0.08	€.0	08			
5	2-Oxo-4-methiolbutyric	≤	0.14	0.13	Special Control of the Control of th				— 0.13
6	Mandelic	S	0.09	0.07				0.07	
7	Phenyllactic	≤	0.10	0.03		0.03			
8	Phenylpyruvic	0.02 -	1.4	0.60		Q.6	j o [
9	Homogentisic	≤	0.23	0.03	0.03				
0	4-Hydroxyphenyllactic	≤	0.62	0.44				0.44	and a
1	N-Acetylaspartic	S	2.5	1.1			1.1>		
2	Malonic	≤	9.9	0.85	0.85				
3	3-Methylglutaric	0.02 -	0.38	0.35		Lawrence .	1		0.35
4	3-Hydroxyglutaric	S	4.6	0.85	0.85				
5	3-Methylglutaconic	0.38 -	2.0	1.2			(1.2)		
В	one Metabolites		i or accounted -						
6	Phosphoric	1 000 -	4 900	1 445	445				

Requisition #:

293081

Physician:

Patient Name:

Jonathan Barnett

Date of Collection:

2/25/2013

Indicator of Fluid Intake

77 *Creatinine

130

mg/dL

*The creatinine test is performed to adjust metabolic marker results for differences in fluid intake. Urinary creatinine has limited diagnostic value due to variability as a result of recent fluid intake. Samples are rejected if creatinine is below 20 mg/dL unless the client requests results knowing of our rejection criteria.

Explanation of Report Format

The reference ranges for organic acids were established using samples collected from typical individuals of all ages with no known physiological or psychological disorders. The ranges were determined by calculating the mean and standard deviation (SD) and are defined as ± 2SD of the mean. Reference ranges are age and gender specific, consisting of Male Adult (≥13 years), Female Adult (≥13 years), Male Child (<13 years), and Female Child (<13 years).


There are two types of graphical representations of patient values found in the new report format of both the standard Organic Acids Test and the Microbial Organic Acids Test.

The first graph will occur when the value of the patient is within the reference (normal) range, defined as the mean plus or minus two standard deviations.


The second graph will occur when the value of the patient exceeds the upper limit of normal. In such cases, the graphical reference range is "shrunk" so that the degree of abnormality can be appreciated at a glance. In this case, the lower limits of normal are not shown, only the upper limit of normal is shown.

In both cases, the value of the patient is given to the left of the graph and is repeated on the graph inside a diamond. If the value is within the normal range, the diamond will be outlined in black. If the value is high or low, the diamond will be outlined in red.

Example of Value Within Reference Range



Example of Elevated Value



Requisition #: Patient Name: 293081


Jonathan Barnett

Physician:

Date of Collection:

2/25/2013

Neurotransmitter Metabolism Markers



The diagram contains the patient's test results for neurotransmitter metabolites and shows their relationship with key biochemical pathways within the axon terminal of nerve cells. The effect of microbial byproducts on the blockage of the conversion of dopamine to norepinephrine is also indicated.

Requisition #:

293081

Physician:

Patient Name:

Jonathan Barnett

Date of Collection:

2/25/2013

Interpretation

High yeast/fungal metabolites (Markers 1,2,3,4,5,6,7,8) indicate a yeast/fungal overgrowth of the gastrointestinal tract. Prescription or natural (botanical) anti-fungals, along with supplementation of high potency multi-strain probiotics (20-50 billion cfu's), may reduce yeast/fungal levels.

High HPHPA (3-(3-hydroxyphenyl)-3-hydroxypropionic acid) (Marker 17) is associated with behavioral, GI, and/or neuropsychiatric effects. GI symptoms may include diarrhea or constipation. Neuropsychiatric effects are more common when values exceed 500 mmol/mol creatinine. HPHPA is an abnormal phenylalanine metabolite produced by GI bacteria of the Clostridia genus, including C. sporogenes, C. botulinum, C. caloritolerans, C. mangenoti, C. ghoni, C. bifermentans, C. difficile, and C. sordelli. Phenylalanine or tyrosine supplements should be avoided because of the possibility of conversion to HPHPA or other toxic byproducts. In most cases, Clostridia overgrowth can be controlled by probiotics supplementation, with 30 billion cfu's/day or more of Lactobacillus rhamnosus GG (Culturelle) and/or at least 2-6 billion cfu's/day of Saccharomyces boulardii.

High 2-oxoglutaric acid (also called alpha-ketoglutaric acid) (Marker 29) may be due to dietary deficiencies of any of several enzyme cofactors or the intake of alpha-ketoglutaric acid (AKG) as a supplement. Conversion of 2-oxoglutaric acid to succinyl-CoA requires the cofactors coenzyme A (derived from pantothenic acid), lipoic acid, FAD derived from riboflavin, and thiamine. Increased conversion of glutamic acid to AKG is another possible explanation. Extremely high values (ten times the upper limit of normal) may be due to genetic enzyme deficiencies and indicate the need for follow-up consultation with a biochemical genetics specialist.

High citric acid (Marker 31) may be due to increased intake of citric acid-containing foods or as a result of intestinal yeast that either produce citric acid or perhaps inhibit the human citric acid cycle. Increased citric acid may also indicate depletion of glutathione, which is required for the enzyme aconitase to metabolize both aconitic and citric acids. If pyroglutamic acid is also high, consider supplements of reduced glutathione, n-acetyl cysteine (NAC), or lipoic acid.

5-hydroxyindoleacetic acid (5-HIAA) levels below the mean (Marker 35) may indicate lower production of the neurotransmitter serotonin. 5-hydroxy-indoleacetic acid is a metabolite of serotonin. Low values have been correlated with symptoms of depression. Supplementation with the precursor 5-HTP (5-hydroxytryptophan) at 50-300 mg/day may be beneficial. Supplementation with tryptophan itself may form the neurotoxic metabolite quinolinic acid, however, 5-HTP is not metabolized to quinolinic acid. Excessive tryptophan supplementation has been associated with eosinophilia myalgia syndrome.

High ethylmalonic, methylsuccinic, adipic, suberic, or sebacic acids (Markers 44,45,46,47,48) may be due to fatty acid oxidation disorders, carnitine deficiency, fasting, or to increased intake of the medium-chain triglycerides found in coconut oil, MCT oil, and some infant formulas. The fatty acid oxidation defects are associated with hypoglycemia, apnea episodes, lethargy, and coma. [An acyl carnitine profile (Duke University Biochemical Genetics Laboratory, http://medgenetics.pediatrics.duke.edu) can rule out fatty acid oxidation defects.] Regardless of cause, supplementation with L-carnitine or acetyl-L-carnitine (500-1000 mg per day) may be beneficial.

Pyridoxic acid (B6) levels below the mean (Marker 50) may be associated with less than optimum health conditions (low intake, malabsorption, or dysbiosis). Supplementation with B6 (20 - 50 mg/day) or a multivitamin may be beneficial.

High pantothenic acid (B5) (Marker 51) indicates high recent intake of pantothenic acid. Pantothenic acid is an essential B vitamin. Since some individuals may require very high doses of pantothenic acid, high values do not necessarily indicate the need to reduce pantothenic acid intake.

Ascorbic acid (vitamin C) levels below the mean (Marker 53) may indicate a less than optimum level of the antioxidant vitamin C. Suggested supplementation is 1000 mg/day of buffered vitamin C, divided into 2-3 doses.

Requisition #:

293081

Physician:

Patient Name:

Jonathan Barnett

Date of Collection:

2/25/2013

High methylcitric acid (Marker 56) is commonly due to biotin deficiency. Biotin is an essential B vitamin. Biotin deficiency may be due to malabsorption, excessive intake of raw egg white, dietary deficiency, or dysbiosis. Methylcitric values greater than 100 mmol/mol creatinine may be due to inborn errors of metabolism involving biotin-dependent enzymes and may require biotin supplementation at very high doses. Methylcitric values of 12-100 mmol/mol creatinine may be due to biotin deficiency. A high quality multivitamin with a minimum of 300 mcg biotin per day is recommended.

Low values for amino acid metabolites (Markers 60-75) indicate the absence of genetic disorders of amino acid metabolism. These markers are deamination (ammonia removed) byproducts that are very elevated only when a key enzyme has low activity; slight elevations may indicate a genetic variation or heterozygous condition which may be mitigated with diet or supplementation. Low values are not associated with inadequate protein intake and have not been proven to indicate specific amino acid deficiencies.

The nutritional recommendations in this test are not approved by the US FDA. Supplement recommendations are not intended to treat, cure, or prevent any disease and do not take the place of medical advice or treatment from a healthcare professional.

Certain uses of the compounds arabinose, citramalic, tartaric, 3-oxoglutaric, carboxycitric, 3,4-dihydroxyphenylpropionic acid, and 3-(3-hydroxyphenyl)-3-hydroxypropionic acid in their application to autism in the Organic Acid Test and Microbial Organic Acid Test are protected by USA patent 5,686,311 granted to The Great Plains Laboratory, Inc., November 11, 1997.